WuXiPRA Appoints Two Key Executives
Feb 06, 2015
SHANGHAI, Feb. 6, 2015 -- WuXiPRA, a leading clinical services company with operations in the greater China region, today announced appointments of two key executives. Liedong Xu was named Executive Vice President and Chief Operations Officer. He brings 22 years of experience in the pharmaceutical and medical device industries, including roles of increasing responsibility at MSD Allergan, Abbott Santen, and Merck Serono. Jason Wu was appointed Executive Vice President and Chief Medical Officer of WuXiPRA. His 20 years of experience in clinical practice, clinical research, and product development include management positions at Graceway, Auxillium, Sanofi, and Pfizer.
In 2012, WuXi PharmaTech and PRA formed the joint venture WuXiPRA to provide comprehensive Phase I-IV clinical trial services in mainland China, Hong Kong and the Asia region. Since then, WuXiPRA has grown to become the third largest clinical CRO in mainland China and Hong Kong, with over 400 employees. It covers all of China's major territories and has offices in Beijing, Shanghai, Wuhan, Hong Kong, and Guangzhou. Its three business divisions focus on full-service clinical studies, embedded strategic consulting, and global clinical informatics, respectively. Services include clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting, and medical monitoring.
"We are very fortunate to have people of the caliber of Liedong and Jason leading our organization," said Kent Thoelke, co-CEO of WuXiPRA and Executive Vice President of PRA Health. "Their combined expertise will allow WuXiPRA to continue to build its successful operations throughout China."
"We are committed to bringing the highest quality of service to pharmaceutical and biotech companies conducting clinical trials in China," said Dr. Ge Li, Chairman of WuXiPRA and Chairman and CEO of WuXi PharmaTech. "Under the leadership of these two talented executives and with strong contributions from everyone on the WuXiPRA team, we will become the leading clinical CRO in China."
For more information, please contact:
Ronald Aldridge (for investors)
Director, Investor Relations
Aaron Shi (for the media)
Director, Corporate Communications
Manager of Public Relations and Corporate Communication